Carsten Reinhardt

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier et al. · Science · 2008 · 1.1K citations

Immunology, Immunoediting, Cancer Patients +18

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 902 citations · Full text

Actively personalized vaccination trial for newly diagnosed glioblastoma

Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel et al. · Nature · 2018 · 897 citations

Vaccination, Neuro-oncology, Vaccination Trial +6

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Steffen Walter, Toni Weinschenk, Arnulf Stenzl et al. · Nature Medicine · 2012 · 777 citations · Full text

Vaccination, Cancer Immunosurveillance, Multipeptide Immune Response +12

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Brian I. Rini, Arnulf Stenzl, Romauld Zdrojowy et al. · The Lancet Oncology · 2016 · 211 citations

Sunitinib Versus Sunitinib, Urology, Genitourinary Cancer +8